Poly Medicure Ltd

- The company raised funds through a Qualified Institutional Placement (QIP) amounting to around INR 1,000 crores in the previous quarter. - Out of the QIP proceeds, INR 500 crores are allocated for new capex, INR 250 crores for general corporate purposes including working capital and acquisitions. - The company currently has around INR 250 crores of cash surplus, which will also be deployed in these areas. - Capex spending of INR 150 crores has already been done from internal accruals in the current 6 months; no QIP money has been used so far for this. - Further capex of INR 100 crores to INR 125 crores will be spent in the next 6 months from internal accruals. - No mention of new or planned fundraising through additional debt or equity beyond this QIP and internal accrual utilization was provided.

- Poly Medicure has planned a capex of INR 500 crores funded mainly through QIP proceeds for setting up three new plants in Haryana, Rajasthan, and Uttarakhand. - These new facilities are expected to be operational by mid to end of FY 2026. - Current capex includes INR 150 crores already spent in the first 6 months of FY 2025 from internal accruals on existing plants for automation and capacity expansion. - Additional capex of INR 100-125 crores is planned in the remaining FY 2025 for adding machines and capacity in current plants. - The new plants will double renal dialysis capacity in the next 2 years and expand product capacities in cardiology and critical care. - INR 250 crores from QIP are earmarked for acquisitions in adjacent therapy areas to accelerate growth via technology and regulatory clearances. - The company also has about INR 250 crores cash surplus for further investments.

- Company targets domestic revenue close to INR 500 crores by year-end with ~500 sales associates. - Sales productivity per rep targeted at around INR 1 crore annually on a blended basis. - Plans to add about 100 new sales associates in FY25; expects to double headcount over next 3-4 years to reach nearly 20,000 hospitals (from current 8,000-9,000). - Expects 20% annual growth rate that will double the business size in 4 years. - Renal business is growing at 50%+ and is expected to constitute 25-28% of total India business soon. - European exports anticipated to grow ~30-35% in coming years; overall export growth guidance is 25-27%. - U.S. business to grow with FDA approvals; first-year revenue expected at USD 2-3 million, with a 3-4 year target of USD 15-20 million. - New plants equipped to double capacity in core segments like renal dialysis by FY26. - Domestic business growth expected at ~20% yearly; maintains cautious margin guidance due to geopolitical uncertainties.

- Company targets a revenue growth of 22% to 24% for the full year, consistent with past guidance. - Domestic business growth is expected at around 20%+, supported by increased market reach. - Renal business is growing rapidly (~50% growth), expected to become 25-28% of India business in near term. - Export business growing at ~27-28%, with Europe growing at 30-35% and US market expanding via FDA approvals. - EBITDA margins expected to improve by 100 to 150 bps, with current margins around 28%, supported by better product mix and scale. - Operating earnings (EBITDA) to benefit from increased volumes, capacity utilization (blended ~60-65%), and automation. - Profit after tax (PAT) increased significantly from past quarters, with INR159 crores in H1 FY25 versus INR119 crores in H1 FY24. - EPS expected to grow gradually as revenue and margin improvement continue with capacity expansion and new product lines.

The transcript/pages from the Poly Medicure Limited Q2 FY25 earnings call do not explicitly mention the current or expected orderbook or pending orders details. However, some relevant points highlighting business outlook and demand include: - Strong growth in renal care business with installation base expected to cross 500 dialysis machines by year-end. - Expansion plans with 3 new manufacturing plants to be operational by mid to end of 2026 to cater to growing demand. - Continuing capacity addition with existing and new plants running at approximately 50-80% utilization. - Robust sales growth in both domestic (20% guidance) and export segments (27-28% growth observed). - Large QIP fund deployment aimed at expanding production and acquisitions to capture more market share. - Increasing demand from European, Indian, and US markets with improved product approvals and traction. - Emphasis on building infrastructure and sales team to reach 20,000 hospitals in India over 3-5 years. No specific numerical orderbook or pending order figures were disclosed in the provided pages.